Chief Executive Officer
Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. Brad has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.
Brad is also a director of Cogstate Inc. and Cogstate Sport Inc. Prior to taking the position of CEO at Cogstate, Brad joined Cogstate as Chief Financial Officer and Company Secretary in May 2004. Prior to that, Brad held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. Brad is a chartered accountant who holds a Bachelor of Business degree
Chief Scientific Officer
Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine.
He has worked extensively on method to identify subtle neurocognitive impairment, and to assess the efficacy of pharmacological treatment, in Alzheimer’s disease, mild cognitive impairment and the HIV dementia complex. He has extended this approach to identify cognitive dysfunction, and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, and attention deficit disorder, developmental dyspraxia and substance abuse in children.
Paul remains an active researcher. He is appointed Professor at the Florey Institute for Neuroscience and Mental Health. He is currently clinical co-chair of the Australian Imaging Biomakers and Lifestyle (AIBL) study. Paul has published over 250 research articles in international peer-reviewed scientific journals, and has co-authored 10 book chapters.
Chief Commercial Officer
Ken Billard is the Chief Commercial Officer for Cogstate, where he develops and executes strategies focused on expanding the adoption of Cogstate solutions to optimize the measurement of cognition and other clinical outcome assessments in pharmaceutical clinical trials.
Ken manages the global sales organization at Cogstate and brings a 30-year track record leading high-performing commercial teams across eClinical, healthcare and technology businesses. Under Ken’s leadership, Cogstate delivers a consultative and customer-focused sales culture based on accountability, integrity, trust and value.
Prior to joining Cogstate, Ken served as Vice President of Business Development and Global Strategic Partnerships at CRF Health (now part of Signant Health), and has held various global leadership roles with invivodata, McKessonHBOC, and CB Technologies.